ATE393764T1 - Polymorphe formen von valsartan - Google Patents
Polymorphe formen von valsartanInfo
- Publication number
- ATE393764T1 ATE393764T1 AT04757623T AT04757623T ATE393764T1 AT E393764 T1 ATE393764 T1 AT E393764T1 AT 04757623 T AT04757623 T AT 04757623T AT 04757623 T AT04757623 T AT 04757623T AT E393764 T1 ATE393764 T1 AT E393764T1
- Authority
- AT
- Austria
- Prior art keywords
- valsartan
- polymorphous forms
- polymorphous
- forms
- crystalline
- Prior art date
Links
- 239000004072 C09CA03 - Valsartan Substances 0.000 title abstract 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title abstract 2
- 229960004699 valsartan Drugs 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45528603P | 2003-03-17 | 2003-03-17 | |
| US47364003P | 2003-05-28 | 2003-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE393764T1 true ATE393764T1 (de) | 2008-05-15 |
Family
ID=33032685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04757623T ATE393764T1 (de) | 2003-03-17 | 2004-03-17 | Polymorphe formen von valsartan |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20040242661A1 (de) |
| EP (1) | EP1511739B1 (de) |
| AT (1) | ATE393764T1 (de) |
| CA (1) | CA2519490A1 (de) |
| DE (1) | DE602004013405T2 (de) |
| ES (1) | ES2238022T3 (de) |
| WO (1) | WO2004083192A1 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7199144B2 (en) | 2003-04-21 | 2007-04-03 | Teva Pharmaceuticals Industries, Ltd. | Process for the preparation of valsartan and intermediates thereof |
| US7378531B2 (en) | 2003-04-21 | 2008-05-27 | Teva Pharmaceutical Industries Ltd | Process for the preparation of valsartan |
| EP1556363A2 (de) * | 2003-04-21 | 2005-07-27 | Teva Pharmaceutical Industries Limited | Verfahren zur herstellung von valsartan und zwischenprodukte davon |
| WO2005049588A1 (en) * | 2003-11-21 | 2005-06-02 | Ranbaxy Laboratories Limited | Process for isolation of valsartan |
| WO2005049587A1 (en) * | 2003-11-21 | 2005-06-02 | Ranbaxy Laboratories Limited | Process for preparation of biphenyl tetrazole |
| EP1661891A1 (de) * | 2004-11-30 | 2006-05-31 | KRKA, D.D., Novo Mesto | Verfahren zur Herstellung von Valsartan |
| EA015108B1 (ru) | 2004-12-24 | 2011-06-30 | КРКА, д.д., НОВО МЕСТО | Способ получения твердой фармацевтической композиции, содержащей валсартан |
| US20060270723A1 (en) * | 2005-01-11 | 2006-11-30 | Tamas Koltai | Process for preparing amorphous valsartan |
| EP1896433A4 (de) * | 2005-05-25 | 2010-06-02 | Ipca Lab Ltd | Neue kristalline formen von (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amin |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| US20070166372A1 (en) * | 2006-01-19 | 2007-07-19 | Mai De Ltd. | Preparation of solid coprecipitates of amorphous valsartan |
| CZ300801B6 (cs) * | 2006-06-07 | 2009-08-12 | Helvetia Pharma A.S. | Kompozice s valsartanem v pevných lékových formách |
| EP2043607A2 (de) * | 2006-06-23 | 2009-04-08 | Usv Limited | Verfahren zur herstellung von mikronisiertem valsartan |
| US20080004313A1 (en) * | 2006-06-28 | 2008-01-03 | Mai De Ltd. | Preparation of crystalline polymorphs of rimonabant hydrochloride |
| EP2057144A4 (de) * | 2006-09-01 | 2010-06-02 | Hetero Drugs Ltd | Neue polymorphe aus rimonabant |
| CN101848700A (zh) | 2007-11-06 | 2010-09-29 | 诺瓦提斯公司 | 基于血管紧张素受体拮抗剂/阻断剂(arb)和中性内肽酶(nep)抑制剂的超结构的双重作用的药物组合物 |
| JP2011513328A (ja) * | 2008-02-28 | 2011-04-28 | ノバルティス アーゲー | バルサルタン固体経口投薬形態及びそのような製剤を製造する方法 |
| US8889213B2 (en) | 2009-01-26 | 2014-11-18 | Teva Pharmaceutical Industries Ltd. | Processes for coating a carrier with microparticles |
| EP2601180A1 (de) | 2010-08-03 | 2013-06-12 | Novartis AG | Hochkristallines valsartan |
| EP3578546A1 (de) | 2013-11-15 | 2019-12-11 | Akebia Therapeutics Inc. | Feste formen von {[5-(3-chlorophenyl)-3-hydroxypyridin-2-carbonyl]amino}essigsäure, zusammensetzungen und verwendungen davon |
| WO2016001844A1 (en) * | 2014-06-30 | 2016-01-07 | Sun Pharmaceutical Industries Limited | Amorphous form of afatinib dimaleate |
| JP6382736B2 (ja) * | 2015-02-02 | 2018-08-29 | 株式会社トクヤマ | バルサルタンの製造方法 |
| JP2016150917A (ja) * | 2015-02-17 | 2016-08-22 | 株式会社トクヤマ | バルサルタンの結晶の製造方法 |
| WO2017012600A1 (en) | 2015-07-20 | 2017-01-26 | Zentiva, K.S. | A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
| US20200276129A1 (en) | 2017-10-13 | 2020-09-03 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Tablet containing valsartan and sacubitril |
| US10703728B1 (en) * | 2019-06-18 | 2020-07-07 | Scinopharm Taiwan, Ltd. | Crystalline form of olaparib and a process for preparing the same |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122010000024I1 (de) * | 1990-02-19 | 2010-07-08 | Novartis Ag | Acylverbindungen |
| US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| US5260325A (en) * | 1991-08-19 | 1993-11-09 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking tertiary amides |
| DE69517832T2 (de) * | 1994-01-28 | 2000-11-09 | Takeda Chemical Industries, Ltd. | Ein Verfahren zur Herstellung von Tetrazolyl-Verbindungen |
| AU1600297A (en) | 1996-02-15 | 1997-09-02 | Novartis Ag | Aryl derivatives |
| GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| IT1292437B1 (it) * | 1997-06-30 | 1999-02-08 | Zambon Spa | Processo di orto-metallazione utile per la sintesi di 1 - tetrazol- 5-il) benzeni 2-sostituiti |
| IT1301759B1 (it) | 1998-06-19 | 2000-07-07 | Nicox Sa | Sali nitrati di farmaci antiipertensivi |
| US6465502B1 (en) * | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
| US6395728B2 (en) * | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
| AU2001267404A1 (en) | 2000-05-04 | 2001-11-12 | Ipf Pharmaceuticals Gmbh | Novel compounds for the treatment of inflammatory and cardiovascular diseases |
| BR0112665A (pt) * | 2000-07-19 | 2003-06-24 | Novartis Ag | Sais |
| US6869970B2 (en) * | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
| UY27668A1 (es) | 2002-02-20 | 2003-10-31 | Pfizer Prod Inc | Composición de ziprasidona y controles sintéticos |
| WO2003089417A1 (en) * | 2002-04-15 | 2003-10-30 | Dr. Reddy's Laboratories Limited | Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2’-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan) |
| GB0222056D0 (en) * | 2002-09-23 | 2002-10-30 | Novartis Ag | Process for the manufacture of organic compounds |
| US7199144B2 (en) * | 2003-04-21 | 2007-04-03 | Teva Pharmaceuticals Industries, Ltd. | Process for the preparation of valsartan and intermediates thereof |
-
2004
- 2004-03-17 EP EP04757623A patent/EP1511739B1/de not_active Expired - Lifetime
- 2004-03-17 US US10/802,627 patent/US20040242661A1/en not_active Abandoned
- 2004-03-17 DE DE602004013405T patent/DE602004013405T2/de not_active Expired - Fee Related
- 2004-03-17 CA CA002519490A patent/CA2519490A1/en not_active Abandoned
- 2004-03-17 AT AT04757623T patent/ATE393764T1/de not_active IP Right Cessation
- 2004-03-17 ES ES04757623T patent/ES2238022T3/es not_active Expired - Lifetime
- 2004-03-17 WO PCT/US2004/008322 patent/WO2004083192A1/en not_active Ceased
-
2005
- 2005-05-27 US US11/140,148 patent/US7105557B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20040242661A1 (en) | 2004-12-02 |
| ES2238022T3 (es) | 2008-11-01 |
| US20050222233A1 (en) | 2005-10-06 |
| CA2519490A1 (en) | 2004-09-30 |
| WO2004083192A1 (en) | 2004-09-30 |
| EP1511739A1 (de) | 2005-03-09 |
| DE602004013405D1 (de) | 2008-06-12 |
| EP1511739B1 (de) | 2008-04-30 |
| US7105557B2 (en) | 2006-09-12 |
| ES2238022T1 (es) | 2005-08-16 |
| DE602004013405T2 (de) | 2009-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004013405D1 (de) | Polymorphe formen von valsartan | |
| NZ592897A (en) | Crystals of laquinimod sodium, and process for the manufacture thereof | |
| HUP0400446A2 (hu) | Azitromicin kristályformái | |
| BRPI0414599A (pt) | pirrol-indóis substituìdos | |
| EP1594979A4 (de) | Oberflächen mit modifizierten nanozylindern | |
| DE60325498D1 (de) | 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen | |
| EP1551357A4 (de) | Gruppe b streptokokken-vakzine | |
| CY1112653T1 (el) | Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης | |
| BRPI0414598A (pt) | indóis substituìdos | |
| MEP15908A (en) | 1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, methods for the production thereof, and their use as antiphlogistics | |
| CY1108808T1 (el) | Ενωσεις μοτιλιδης | |
| UA93531C2 (en) | Novel hydrogen sulfate salt | |
| NO20071254L (no) | Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav. | |
| DK1546122T3 (da) | Fremgangsmåde til fremstilling af valsartan | |
| NO20062021L (no) | Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika | |
| BRPI0513149A (pt) | uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituìdas no tratamento de náuseas e vÈmito | |
| ATE461182T1 (de) | Kristallines mycophenolat-natrium | |
| NO20070550L (no) | Fremgangsmate for fremstilling av pyrrolotriazinforbindelser | |
| NO20083269L (no) | Prosess for a anvende krystallinsk orlistatmetoder | |
| DE602005015963D1 (de) | Estergebundene makrolide, die sich für die behandlung von mikrobiellen infektionen eignen | |
| TW200510323A (en) | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | |
| ATE410166T1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit | |
| CL2008002377A1 (es) | Procedimiento de preparacion de compuestos derivados de 3-piperidin-4-il-1,3,4,5-tetrahidro-benzo[d][1,3]diazepin-2-ona; compuestos intermediarios; y su procedimiento de preparacion. | |
| NO20091386L (no) | Fenyloksyanilinderivater | |
| EP1565448A4 (de) | VERFAHREN ZUR HERSTELLUNG VON10H-DIBENZOçB, F] ç1,4]THIAZEPIN-11-ON |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |